Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Patel on Sequencing Therapy in Rectal Cancer

November 28th 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

November 18th 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Eng on Unmet Needs in Early-Onset CRC

November 12th 2019

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Novel Strategies Progress Through mCRC Pipeline

November 6th 2019

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

Wnt Pathway Emerges as Attractive Target in CRC

November 4th 2019

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Genetic Testing Guides mCRC Treatment

November 4th 2019

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

November 1st 2019

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

MRTX849 Active in KRAS G12C+ NSCLC and CRC

October 29th 2019

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Targeting Wnt in BRAF-Mutant Colorectal Cancer

October 28th 2019

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

Addressing the Needs of Molecular Subgroups in CRC

October 28th 2019

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRC

October 26th 2019

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Pivotal Study Examines Blood Test as CRC Screening Method

October 24th 2019

In an effort to improve colorectal cancer screening rates via a less invasive method, the registrational ECLIPSE is evaluating the performance of the LUNAR-2 blood test in detecting colorectal cancer in average-risk adults.

Dr. Kasi on the Prognostic Value of ctDNA in CRC

October 24th 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Dr. Weinberg on Targeted Therapies for Molecular Subsets of mCRC

October 17th 2019

Benjamin Weinberg, MD, discusses treatment strategies for patients with different molecular subtypes of metastatic colorectal cancer.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.